All In Biotech

Drug Trial Radar · NCT01301898

To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients

Randomized, Single-blind, Active-controlled, Phase 1/2 Study to Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome (Mucopolysaccharidosis II) Patients

Last checked: Nov 20, 2026Latest source record: Feb 14, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

31

Actual

Start

May 2010

Primary completion

Mar 2011

Study completion Mar 2011

Sponsor

Lead sponsor
Green Cross CorporationIndustry
Sponsor type
Industry
First posted
Feb 23, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
Who can join
Male only, from 6 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of GC1111 (recombinant human iduronate-w-sulfatase) in Hunter Syndrome (Mucopolysaccharidosis II) patients

Conditions

  • Mucopolysaccharidosis II

Interventions

  • GC1111_0.5mg/kgDrug

  • GC1111_1.0mg/kgDrug

  • Elaprase_0.5mg/kgDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary OutcomeTime frame: baseline, every 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Samsung Medical Center

    Seoul, Irwon-dong, Gangnam-Gu, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.